Navigation Links
Growth hormone is used to treat twice as many short boys than girls in the US and Asia
Date:4/17/2008

Boys are twice as likely as girls in the U.S. and Asia (mostly Japan) to receive recombinant human growth hormone (rhGH) for growth hormone deficiency, illnesses that affect height, and short stature of a non-medical nature. A smaller gender difference exists in Europe, Australia and New Zealand, but in the rest of the world short boys and girls are treated at the same rate. This indicates a likely cultural bias for male height in some countries.

The study, by researchers from The Childrens Hospital of Philadelphia and Pfizer, is electronically available prior to publication in the Journal of Clinical Endocrinology and Metabolism.

All children entered in the Pfizer International Growth Study (KIGS), a database designed to document long-term outcomes and safety of Genotropin, one of the three leading commercial brands of rhGH, were categorized by gender, location, date and age of therapy initiation, and diagnosis. Measures of national health status, health care expenditures, general economic indices and mean adult heights were also compared. Children were categorized into four geographic regions including the U.S., Europe/Australia/New Zealand, Asia and the Rest of the World.

Recombinant human growth hormone has been available since 1985. Because reports found more U.S. males receiving rhGH in its first years of availability, and rhGH use has increased considerably over the past 20 years, we thought it was important to get an up-dated look at the gender-based patterns of use in the U.S. and how they compared to other countries, said Adda Grimberg, M.D., lead author of the study and a pediatric endocrinologist at The Childrens Hospital of Philadelphia. We suspect that social and cultural pressures, combined with financial constraints, contribute to the international differences in the gender distributions of children treated with rhGH.

Historical trends revealed a consistent overall male predominance among U.S. pediatric rhGH recipients at a nearly two-to-one ratio. The gender ratio did not change significantly across the more than 20 years of rhGH use. Males outnumbered females at all ages, especially during the second decade of life. Because boys typically start puberty later than girls and hit their growth spurt at a later stage of puberty, boys who lag behind their peers are more likely to be perceived as having a growth problem.

The factor that most consistently affected the gender distribution was the diagnostic indication for rhGH therapy. The greatest gender disparities occurred for diagnoses without an identifiable cause, such as idiopathic short stature and idiopathic GH deficiency because of the complexity of the diagnostic tests. Prader-Willi syndrome, a genetic disease with multiple benefits from rhGH therapy besides height, was the only indication with gender equality in the U.S. Dr. Grimberg hypothesized, when the decision to treat involves an indication that relies more heavily on clinical judgment, treatment patterns are more likely to highlight underlying differences in social pressures for tallness.

Comparing the U.S. experience with global patterns revealed that Asia (mostly Japan) had the greatest male predominance at 65 percent, followed closely by the U.S. at 64 percent. Europe/Australia/New Zealand came third at 55 percent. All three world regions exceeded 50 percent males, while the rhGH recipients in the rest of the world regions, where rhGH is used far less frequently, were 47 percent male. Similar to the U.S. data, global gender distributions of rhGH depended on the specific reason the therapy was initiated. The United Kingdom had the lowest male percentage of the top 10 country-based children prescribed Genotropin.

Dr. Grimbergs earlier research in referral patterns for growth failure evaluations at a U.S. pediatric endocrinology clinic showed a disturbing statistic: that 41 percent of the girls were found to have an underlying disease that made them short, compared to 15 percent of the boys. Conversely, 38 percent of the boys were within normal height ranges, compared to 20 percent of the girls, and boys were referred for evaluation about twice as often as girls.

A variety of diseases may cause growth failure among them, hormone deficiencies, Turner syndrome (a chromosome abnormality found only in females) and gastrointestinal conditions such as celiac disease or inflammatory bowel disease. For some, growth failure is the only symptom. Gender differences in the use of rhGH may be indicative of more general gender differences in the diagnostic rates of diseases that present solely with growth failure, cautioned Dr. Grimberg. Not all of these diseases are treated by rhGH. For example, celiac disease is treated with a gluten-free diet. If a short girl is less likely to be perceived as needing rhGH treatment, she may also be less likely to undergo the diagnostic evaluation that reveals her underlying celiac disease.

The manufacture of rhGH in 1985 changed the treatment of pediatric growth failure. Prior to 1985, only children with the most severe growth hormone deficiency were treated because of the very limited supply of human pituitary GH. In 2003, the U.S. Food & Drug Administration (FDA) approved the use of rhGH for the treatment of idiopathic short stature, for children who are significantly shorter than their peers yet do not have an identifiable underlying disease.


'/>"/>

Contact: Joey Marie McCool
McCool@email.chop.edu
267-426-6070
Children's Hospital of Philadelphia
Source:Eurekalert

Related medicine news :

1. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
2. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
3. Greenway Medical Technologies Experiences Continued Growth in OB/GYN Marketplace
4. BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond
5. Exercise may lead to faster prostate tumor growth
6. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
7. The Massage Spot Announces Opening of Manhattan Beach Location; Seeks Investors for Growth of Affordable Luxury Mini Day Spa Concept
8. Too many gene copies stimulate tumor cell growth
9. Data-handling technique finds genes to be team players in curbing brain cancer cell growth
10. Ingredient found in green tea significantly inhibits breast cancer growth in female mice
11. CompareNetworks, Inc. Fuels Growth by Raising Round of Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: